• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma

by MM360 Staff | Jul 3, 2025 | Myeloma News

Source: Pharmacy Times articles The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma. Read More

Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers

by MM360 Staff | Jul 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

by MM360 Staff | Jul 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways

by MM360 Staff | Jul 1, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma

by MM360 Staff | Jun 30, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease

by MM360 Staff | Jun 27, 2025 | Myeloma News

Source: Pharmacy Times articles Shaji Kumar, MD, shares data and insights from the phase 2 RedirecTT-1 study. Read More
« Older Entries
Next Entries »

Recent Content

  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs
  • Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
  • Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT